Compare Citius Pharmaceuticals Inc (CTXR) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while First Trust Cloud Computing ETF trades at $174.2 (market cap $3.47B). The key difference: First Trust Cloud Computing ETF is far larger — about 254.8× Citius Pharmaceuticals Inc's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and First Trust Cloud Computing ETF for 85 Days on average.
| CTXR | SKYY | |
|---|---|---|
Market Cap | $13.62M | $3.47B |
Volume | 132,438 | 176,159 |
Sector | Health | — |
52-Week High | $1.82 | $171.01 |
52-Week Low | $0.48 | $104.16 |
Typical Hold Time | 16 Days | 85 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
First Trust Cloud Computing ETF (SKYY) trades at $174.09, up 1.94% with bullish technical signals from moving averages. The ETF recently hit a new 52-week high, reflecting strong momentum in cloud computing stocks driven by AI infrastructure demand. Technical indicators show support at $169 and resistance at $171-173, with the current price near recent highs.
SKYY offers diversified exposure to cloud infrastructure and software companies benefiting from secular trends in AI adoption and digital transformation. Key risks include sector concentration and market volatility, while institutional sentiment remains positive given the long-term growth prospects in cloud computing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
